A new study published in The Lancet reveals that semaglutide, a medication commonly known as Ozempic, has been found to reduce the symptoms of peripheral artery disease (PAD) in people with diabetes. PAD is a condition characterized by narrowed arteries that restrict blood flow to the arms and legs, leading to complications such as tingling, numbness, and cramping in the legs.
The study, called STRIDE, involved 792 participants with diabetes and PAD who were divided into two groups: one received semaglutide injections, while the other received a placebo. After one year, the participants who took semaglutide showed significant improvements in their quality of life and ability to walk without pain. They also reported better ankle-brachial indices, a test that measures blood flow to the lower limbs.
The results suggest that semaglutide can help reduce the symptoms of PAD in people with diabetes beyond its weight loss benefits. According to Dr. Subodh Verma, one of the co-leads of the study, the drug’s benefits for early-stage PAD appeared to be largely independent of weight loss.
This is a significant development, as PAD can lead to lower limb amputations if left untreated. The study’s findings reinforce the importance of semaglutide as a treatment option for diabetes beyond its original use for weight management. With 10-20% of people with diabetes developing PAD, this new information could have a substantial impact on improving patient outcomes.
As Dr. Lawrence Leiter noted, “Semaglutide is already widely used in the treatment of diabetes. It’s a disease-modifying therapy that offers another advantage beyond weight loss.” The study’s results will be closely watched by healthcare professionals and patients as they consider incorporating semaglutide into their treatment plans for PAD.
Source: https://www.theglobeandmail.com/canada/article-semaglutide-or-ozempic-reduces-symptoms-of-feared-diabetes